Navigation Links
Biopure Operations Compliant With U.K. Manufacturing Guidelines
Date:4/11/2008

CAMBRIDGE, Mass., April 11 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has found the company's Pennsylvania manufacturing facility to be in general compliance with the principles and guidelines of good manufacturing practices as identified in the Commission Directives. The company received confirmation that it has responded successfully to the issues classified as "Other" in the MHRA's original inspection letter. The original inspection report contained no "Critical" or "Major" deficiencies.

As previously announced, Biopure has been invited by the MHRA to meet with the MHRA team of reviewers to discuss issues still outstanding from the application for registration of Hemopure for use in the treatment of acute anemia following orthopedic surgery blood loss when blood is not readily available or not an option. The company intends to announce the date of this meeting when it is set, as well as the outcome of the meeting and an anticipated timeline for the resolution of issues.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. The company is developing Hemopure for other indications and is supporting the U.S. Navy's government- funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R)[hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 200,000 units of Oxyglobin since 1998.

Statements in this release that are not strictly historical are forward- looking statements, including any statements implying that the company will be able to respond to the MHRA questions or that Hemopure will attain marketing authorization in the United Kingdom and including statements implying that any clinical trial will be initiated and/or carried out to completion or that study results will be as desired, and any statements that might imply that Hemopure may receive marketing approval in the UK or any other jurisdictions or for additional indications in South Africa. Actual results and their timing may differ materially from those projected in these forward-looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, including its limited cash resources and need to raise additional capital to pursue its business, the company's ability to satisfactorily address the issues raised in the MHRA correspondence or additional issues raised at a later date, unexpected costs and expenses, delays and adverse determinations by regulatory authorities, unanticipated problems with the product's commercial use, whether or not product related, and with product distributors, sales agents or other third parties, delays in clinical trials, and the other factors identified under the heading "Risk Factors" in the Company's quarterly report on Form 10-Q filed on March 17, 2008, which can be accessed in the EDGAR database at the U.S. Securities and Exchange Commission's (SEC) website, http://www.sec.gov. The company undertakes no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. A full discussion of the company's operations and financial condition can be found in the company's filings with the SEC.

Contact: Tiana Gorham

Biopure Corporation

(617) 234-6826

IR@biopure.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biopure Appoints New Independent Auditor
2. Biopure Completes U.K. Regulatory Agency Inspection
3. Biopure Announces 2008 First Quarter Financial Results
4. Biopure Launches Updated Website
5. Biopure Announces Pricing of Equity Offering
6. Biopure Gives Update on Malaysia Joint Venture Discussions
7. Genta Restructures Operations to Focus on Priority Initiatives
8. NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations
9. NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
10. Mentice AB Announces Leadership Changes Within Its Worldwide Operations
11. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a leading provider ... the occasion with a strong presence at Bio-IT World Conference & Expo 2017 ... an invitation to all attendees to view posters on the entire range ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... as Vice President of Clinical Operations. She brings years of expertise in ... Therapeutics. From her professional foundation as a licensed occupational therapist, through a variety ...
(Date:5/22/2017)... ... 22, 2017 , ... Baltimore biotech firm, PathSensors, announced that ... in developing and issuing recommendations to grow Maryland's biohealth industry and position the ... , The recommendations are contained in a report from the ...
(Date:5/19/2017)... ... May 19, 2017 , ... The University City Science Center ... ripe for commercialization, and who are affiliated with the 21 partner academic and ... QED, now in its tenth round, is the first multi-institutional proof-of-concept program for ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ... of online age and identity verification solutions, announced today ... Identity Conference 2017, May 15 thru May 17, 2017, ... Building and International Trade Center. Identity ... globe and in today,s quickly evolving digital world, defining ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert in ... media edge server, the M820, which features the company,s hybrid codec ... provided by Tera Probe, Inc., will be showcased during the upcoming ... NAB show at the Las Vegas Convention ... Click ...
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
Breaking Biology News(10 mins):